Medipal
Category: AI in Healthcare
A digital healthcare startup operating Afterdoc, a B2B SaaS solution for post-treatment patient management in hospitals and clinics, and recently launched Medipal AI, an app-store style AI agent platform for medical institutions. Medipal was founded in 2020. The company is led by Kang Jong-il (강종일). Based in Seoul, South Korea. Team size: 11-50. Total funding raised: $5.4M. Latest round: Series A. Key investors include Base Investment (베이스인베스트먼트), Insight Equity Partners (인사이트에퀴티파트너스), KT Investment (KT인베스트먼트), Sopoong Ventures (소풍벤처스), MYSC (엠와이소셜컴퍼니), Digital Healthcare Partners (DHP).
- Founded
- 2020
- Headquarters
- Seoul, South Korea
- Team size
- 11-50
- Total funding
- $5.4M
Value proposition
Medipal provides an AI-powered patient management platform (Afterdoc) and AI agent marketplace (Medipal AI) that helps hospitals and clinics improve patient revisit rates, streamline operations, and enhance patient experience through AI coaching, global patient coordination, and automated call management — without replacing staff, but augmenting their capabilities.
Products and solutions
Afterdoc (재진 환자 관리 솔루션) — B2B SaaS for post-treatment patient management, Medipal AI — AI agent platform with AI Consultation Coach, AI Global Coordinator, AI Call Manager, AI Appointment Scheduler
Unique value
App-store style AI agent platform purpose-built for medical institutions, powered by 5 years of real-world patient management data (500+ clinics, 1.5M+ patients, 20M+ consultation records), enabling clinics to customize and deploy AI agents that learn and improve over time.
Target customer
Hospitals and clinics (primary and secondary care) in South Korea and expanding to Vietnam
Industries served
Healthcare / Digital Health / Medical Clinics
Technology advantage
5 years of accumulated real-world patient management data (500+ clinics, 1.5M+ patients, 20M+ consultation records); AI agents that are customizable per clinic workflow and improve through reinforcement learning; EMR integration partnerships with leading Korean EMR providers (Jeonneung IT, TNH)
How they differentiate
Unlike competitors who focus on replacing staff with AI, Medipal positions AI as a staff augmentation tool. Their platform is built on 5 years of real patient management data from Afterdoc, giving them a unique data moat. The app-store model allows clinics to pick and choose specific AI agents they need, with customization per clinic workflow.
Main competitors
Motionlabs (리비짓), Broad CNS (보나), Lemon Healthcare (레몬케어365), Wise AI (에이유)
Key partnerships
Jeonneung IT (전능아이티) — EMR integration partnership (2023), TNH (티엔에이치) — EMR integration partnership (2025), H+ Yangji Hospital — Vietnam market expansion partnership (2025), Korean Society of Emergency Medicine — solution adoption agreement (2022)
Notable customers
500+ hospitals and clinics in South Korea including Incheon Sejong Hospital (종합병원), H+ Yangji Hospital (H+ Hanoi, Vietnam)
Major milestones
2020-06: Company founded, 2020-07: Seed funding from Sopoong Ventures and MYSC, 2021-09: Afterdoc SaaS launched, 2022-05: ₩1.5B Pre-Series A funding, 2023-11: ₩5B Series A funding (cumulative ~₩7B), 2025-07: First overseas expansion to Vietnam via H+ Yangji Hospital partnership, 2025-11: First monthly profit achieved, 2025-12: 500+ clinic contracts milestone, 2026-04: Medipal AI platform launched, 2026-Q1: Quarterly profit achieved, revenue 5x YoY
Growth metrics
500+ hospitals/clinics contracted; 1.5M+ patients served; 20M+ cumulative consultation records; 30 employees (as of Apr 2026); Monthly profit achieved Nov 2025; Q1 2026 quarterly profit; Revenue 5x growth YoY (2025→2026)
Market positioning
Leading digital health startup in Korea's post-treatment patient management SaaS market, now expanding into AI agents for healthcare. First Korean digital health company to enter Vietnam's $2.5B digital health market through H+ Yangji Hospital partnership.
Geographic focus
South Korea (primary), Vietnam (expanding)
Patents and IP
7 patents registered (as of Feb 2026 per THE VC)
About Kang Jong-il (강종일)
KAIST Social Enterprise MBA (Class of 2019); Founder & CEO of Medipal since 2020
Official website: https://www.medipal.co.kr